Saurabh Saha Sells 87,496 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 87,496 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $10,626,702.06. This represents a 13.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total value of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.53, for a total transaction of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA traded up $1.18 during midday trading on Friday, reaching $18.67. The company had a trading volume of 690,784 shares, compared to its average volume of 419,328. Centessa Pharmaceuticals plc has a 52-week low of $6.15 and a 52-week high of $18.77. The company's 50 day moving average price is $16.36 and its 200 day moving average price is $12.90. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.46 billion, a P/E ratio of -11.82 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. As a group, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. First Light Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock valued at $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC raised its stake in Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock valued at $35,518,000 after acquiring an additional 850,000 shares during the period. FMR LLC lifted its holdings in Centessa Pharmaceuticals by 4.6% during the third quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after purchasing an additional 129,300 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Centessa Pharmaceuticals by 54.1% during the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after purchasing an additional 953,659 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CNTA shares. Guggenheim raised their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective on the stock. Oppenheimer reiterated an "outperform" rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. BMO Capital Markets boosted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a report on Monday, September 16th. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.